Literature DB >> 15887969

Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.

In-Hae Kim1, Fenton R Heirtzler, Christophe Morisseau, Kosuke Nishi, Hsing-Ju Tsai, Bruce D Hammock.   

Abstract

Soluble epoxide hydrolase (sEH) plays an important role in the metabolism of endogenous chemical mediators involved in the regulation of blood pressure and inflammation. 1,3-Disubstituted ureas with a polar group located on the fifth atom from the carbonyl group of urea function are active inhibitors of sEH both in vitro and in vivo. However, their limited solubility in water and relatively high melting point lead to difficulties in formulating the compounds and poor in vivo efficacy. To improve these physical properties, the effect of structural modification of the urea pharmacophore on the inhibition potencies, water solubilities, octanol/water partition coefficients (log P), and melting points of a series of compounds was evaluated. For murine sEH, no loss of inhibition potency was observed when the urea pharmacophore was modified to an amide function, while for human sEH 2.5-fold decreased inhibition was obtained in the amide compounds. In addition, a NH group on the right side of carbonyl group of the amide pharmacophore substituted with an adamantyl group (such as compound 14) and a methylene carbon present between the adamantyl and amide groups were essential to produce potent inhibition of sEH. The resulting amide inhibitors have 10-30-fold better solubility and lower melting point than the corresponding urea compounds. These findings will facilitate synthesis of sEH inhibitors that are easier to formulate and more bioavailable.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15887969      PMCID: PMC1450255          DOI: 10.1021/jm0500929

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  29 in total

Review 1.  A new class of lipid mediators: cytochrome P450 arachidonate metabolites.

Authors:  M A Carroll; J C McGiff
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

2.  Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids.

Authors:  K Node; X L Ruan; J Dai; S X Yang; L Graham; D C Zeldin; J K Liao
Journal:  J Biol Chem       Date:  2001-02-22       Impact factor: 5.157

3.  Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.

Authors:  Z Yu; F Xu; L M Huse; C Morisseau; A J Draper; J W Newman; C Parker; L Graham; M M Engler; B D Hammock; D C Zeldin; D L Kroetz
Journal:  Circ Res       Date:  2000-11-24       Impact factor: 17.367

4.  Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties.

Authors:  Gianfranco Balboni; Remo Guerrini; Severo Salvadori; Clementina Bianchi; Daniela Rizzi; Sharon D Bryant; Lawrence H Lazarus
Journal:  J Med Chem       Date:  2002-01-31       Impact factor: 7.446

5.  Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B.

Authors:  Scott D Larsen; Tjeerd Barf; Charlotta Liljebris; Paul D May; Derek Ogg; Theresa J O'Sullivan; Barbara J Palazuk; Heinrich J Schostarez; F Craig Stevens; John E Bleasdale
Journal:  J Med Chem       Date:  2002-01-31       Impact factor: 7.446

6.  Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension.

Authors:  John D Imig; Xueying Zhao; Jorge H Capdevila; Christophe Morisseau; Bruce D Hammock
Journal:  Hypertension       Date:  2002-02       Impact factor: 10.190

7.  Rapid determination of soluble epoxide hydrolase inhibitors in rat hepatic microsomes by high-performance liquid chromatography with electrospray tandem mass spectrometry.

Authors:  T Watanabe; B D Hammock
Journal:  Anal Biochem       Date:  2001-12-15       Impact factor: 3.365

8.  Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells.

Authors:  B Yang; L Graham; S Dikalov; R P Mason; J R Falck; J K Liao; D C Zeldin
Journal:  Mol Pharmacol       Date:  2001-08       Impact factor: 4.436

9.  Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation.

Authors:  C J Sinal; M Miyata; M Tohkin; K Nagata; J R Bend; F J Gonzalez
Journal:  J Biol Chem       Date:  2000-12-22       Impact factor: 5.157

10.  Evaluation of fish models of soluble epoxide hydrolase inhibition.

Authors:  J W Newman; D L Denton; C Morisseau; C S Koger; C E Wheelock; D E Hinton; B D Hammock
Journal:  Environ Health Perspect       Date:  2001-01       Impact factor: 9.031

View more
  47 in total

Review 1.  Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.

Authors:  Hong C Shen; Bruce D Hammock
Journal:  J Med Chem       Date:  2012-01-17       Impact factor: 7.446

2.  Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase.

Authors:  Stevan Pecic; Shi-Xian Deng; Christophe Morisseau; Bruce D Hammock; Donald W Landry
Journal:  Bioorg Med Chem Lett       Date:  2011-10-28       Impact factor: 2.823

3.  Antitumor agents. 289. Design, synthesis, and anti-breast cancer activity in vivo of 4-amino-2H-benzo[h]chromen-2-one and 4-amino-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one analogues with improved water solubility.

Authors:  Yizhou Dong; Kyoko Nakagawa-Goto; Chin-Yu Lai; Susan L Morris-Natschke; Kenneth F Bastow; Yoon Kim; Eva Y-H P Lee; Kuo-Hsiung Lee
Journal:  J Nat Prod       Date:  2012-02-03       Impact factor: 4.050

4.  Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties.

Authors:  Shao-Xu Huang; Hui-Yuan Li; Jun-Yan Liu; Christophe Morisseau; Bruce D Hammock; Ya-Qiu Long
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

5.  Symmetric adamantyl-diureas as soluble epoxide hydrolase inhibitors.

Authors:  Vladimir Burmistrov; Christophe Morisseau; Kin Sing Stephen Lee; Diyala S Shihadih; Todd R Harris; Gennady M Butov; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2014-03-20       Impact factor: 2.823

6.  Effects of adamantane alterations on soluble epoxide hydrolase inhibition potency, physical properties and metabolic stability.

Authors:  Vladimir Burmistrov; Christophe Morisseau; Todd R Harris; Gennady Butov; Bruce D Hammock
Journal:  Bioorg Chem       Date:  2017-12-30       Impact factor: 5.275

7.  Solid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitors.

Authors:  Sung Hee Hwang; Christophe Morisseau; Zung Do; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2006-09-01       Impact factor: 2.823

8.  Development of a high-throughput screen for soluble epoxide hydrolase inhibition.

Authors:  Nicola M Wolf; Christophe Morisseau; Paul D Jones; Bertold Hock; Bruce D Hammock
Journal:  Anal Biochem       Date:  2006-05-11       Impact factor: 3.365

9.  Structure-activity relationships of substituted oxyoxalamides as inhibitors of the human soluble epoxide hydrolase.

Authors:  In-Hae Kim; In-Hee Lee; Hisashi Nishiwaki; Bruce D Hammock; Kosuke Nishi
Journal:  Bioorg Med Chem       Date:  2014-01-03       Impact factor: 3.641

Review 10.  The 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic pain.

Authors:  Sean D Kodani; Bruce D Hammock
Journal:  Drug Metab Dispos       Date:  2015-03-11       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.